Evidence map›Paper›PMID 34487283›Full record

ArticleEJNMMI research2021

A novel read methodology to evaluate the optimal dose of

Colin G Miller, Henning Grønbæk, Irene Virgolini, Andreas Kjaer, Pierre Terve, Shadfar Bahri, Peter Iversen, Hanna Svirydenka, Thomas Rohban, Sandy McEwan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 5 countries.

Colin G MillerThe Bracken Group for Ipsen Bioscience, 12 Penns Trail, Newtown, PA, 18940, USA. cmiller@thebrackengroup.com.ORCID http://orcid.org/0000-0002-9286-9787
Henning GrønbækDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Irene VirgoliniDepartment of Nuclear Medicine, University of Innsbruck, Innsbruck, Austria.
Andreas KjaerDepartment of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Pierre TerveKeosys, Nantes, France.
Shadfar BahriAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
Peter IversenDepartment of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark.
Hanna SvirydenkaDepartment of Nuclear Medicine, University of Innsbruck, Innsbruck, Austria.
Thomas RohbanPartner 4 Health for Ipsen Bioscience, Paris, France.
Sandy McEwanIpsen Bioscience, Cambridge, MA, USA.
Aarhus University Hospital · DKUniversität Innsbruck · ATIpsen (France) · FRIpsen (United States) · USMolecular Theranostics (United States) · USResearch Institute for Bioscience and Biotechnology · NPUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

resultsTotal image quality score for

conclusionsBinary visual reading, which was associated with a low inter-reader variability, has further supported that the optimal administered radioactivity of

Indexed as

68Ga-satoreotide trizoxetanBinary visual readingDiagnostic imagingNeuroendocrine tumoursSomatostatin receptor antagonist

Identifiers

PMID34487283
PMCPMC8421477
OpenAlexW3198146107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.